Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with EGFR-mutated non-small cell lung cancer (NSCLC) – and now ...

Johnson & Johnson (NYSE: JNJ) has announced important overall survival (OS) results from the Phase III MARIPOSA study.

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...

Johnson & Johnson’s (J&J’s) Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by one year above the standard of care ...